272 related articles for article (PubMed ID: 11404068)
1. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Biedenbach DJ; Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
Jones RN; Biedenbach DJ
Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
[TBL] [Abstract][Full Text] [Related]
3. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
Jones RN; Biedenbach DJ; Erwin ME; Beach ML; Pfaller MA
J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
5. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
Gales A; Sader H; Jones RN;
Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
Bell JM; Turnidge JD; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
[TBL] [Abstract][Full Text] [Related]
7. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
Jones ME; Staples AM; Critchley I; Thornsberry C; Heinze P; Engler HD; Sahm DF
Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
[TBL] [Abstract][Full Text] [Related]
8. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
[TBL] [Abstract][Full Text] [Related]
9. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
Blondeau JM; Vaughan D; Laskowski R; Borsos S;
Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.
Bell JM; Turnidge JD; Jones RN;
Int J Antimicrob Agents; 2002 Feb; 19(2):125-32. PubMed ID: 11850165
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.
Jones ME; Blosser-Middleton RS; Critchley IA; Karlowsky JA; Thornsberry C; Sahm DF
Clin Microbiol Infect; 2003 Jul; 9(7):590-9. PubMed ID: 12925097
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Kitzis MD; Goldstein FW; Miegi M; Acar JF
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
15. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2000 Apr; 36(4):255-9. PubMed ID: 10764968
[TBL] [Abstract][Full Text] [Related]
17. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
Koeth LM; Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Appelbaum PC
Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Brueggemann AB; Kugler KC; Doern GV
Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
